Detalhe da pesquisa
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37879077
2.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38591430
3.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38695144
4.
A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
Ann Hematol
; 102(12): 3427-3430, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37713123
5.
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Am J Hematol
; 98(10): 1619-1626, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37485584
6.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol
; 98(10): E281-E284, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37515433
7.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
N Engl J Med
; 380(22): 2095-2103, 2019 05 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31141631
8.
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Am J Hematol
; 97(5): 574-582, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35150150
9.
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
Am J Hematol
; 97(11): 1427-1434, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36053747
10.
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Am J Hematol
; 97(11): 1413-1418, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36054032
11.
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Am J Hematol
; 97(7): 856-864, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35357036
12.
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
Am J Hematol
; 97(9): 1135-1141, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35713551
13.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Am J Hematol
; 97(8): 1035-1043, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35583199
14.
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Cancer
; 127(20): 3772-3781, 2021 10 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34255353
15.
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
Cancer
; 127(14): 2489-2499, 2021 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33793970
16.
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Cancer
; 127(22): 4213-4220, 2021 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34343352
17.
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Cancer
; 127(12): 2025-2038, 2021 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33740268
18.
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Br J Haematol
; 195(3): 378-387, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34340254
19.
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Haematologica
; 106(8): 2121-2130, 2021 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33853292
20.
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Am J Hematol
; 96(3): 282-291, 2021 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33264443